Case Report

Post-delivery Hypoglycemia in Type 1 Diabetic Patient is associated with Lactation: A case presentation

José G Jiménez-Montero*
Department of Endocrinology Hospital CIMA, San José, Costa Rica and Postgraduate Studies, Universidad de Ciencias Médicas, PO Box 638 -1007, Centro Colon, San José, Costa Rica

Abstract

Objective: To describe diabetes management during pregnancy and after delivery of a pregnant type-I diabetic patient with hyperemesis gravidarum.

Methods: The patient’s history, laboratory results, and glycemic control were obtained. Diabetes control was done using an insulin pump and a glucose monitoring system during pregnancy, post-partum and at six month after delivery.

Results: A 27-year–old pregnant patient with history of hypothyroidism, type 1 diabetes, and hyperemesis gravidarum, receiving multiple daily insulin injections, presented marked glycemic fluctuations starting on week 6 of gestation. Before conception laboratory results showed glycosylated hemoglobin A1c (HbA1c) at 6.7% and Thyroid-Stimulating Hormone (TSH) at 4.40 uUI/ml. An insulin pump and a continuous glucose monitoring system improved glycemic control as mean glucose changed from 139±77 mg/dL in the first trimester to 113.0±44 mg/dL and 106.0±39 mg/dL, in the second and third trimester (p<0.01) respectively. HbA1c declined from 6.7% to 5.6%. Adjustment in levothyroxine doses optimized thyroid hormone levels. The patient gave birth on week 39 of pregnancy by Caesarean section to a child of 2,700 g and 48 cm, and an Apgar score of 9/10. Recurrently poglycemic episodes occurred 10-15 minutes after initiating lactation followed by rebound hyperglycemic events; once the patient ceased lactation six months later glycemic controls improved.

Conclusions: Optimal glycemic control was achieved during pregnancy, but the lactation period induced sudden glucose fluctuations. Recurring hypoglycemic events lead to a decline in post-partum glycemic control. Thus, lactation-induced hypoglycemia may explain the frequent deterioration in glycemic control in type-I diabetic patients.

Keywords: Type 1 diabetes; Lactation-induced hypoglycemia; Continuous insulin infusion; Continuous glucose monitoring system

Abbreviation: TSH: Thyroid-Stimulating Hormone; CSII: Continuous Insulin Infusion; CGMS: Glucose Monitoring System

Introduction

In diabetic pregnant patients, a strict glycemic control is critical to avoid fetal malformations, neonatal morbidity and obstetrical complications [1-5]. However, in type 1 diabetics an aggressive insulin treatment increases the risk of severe hypoglycemia and has potential adverse maternal effects [6,7]. Recurrent hypoglycemic events induce
rebound hyperglycemia due to counter regulatory mechanisms and food intake [8]. Postprandial hyperglycemia during pregnancy has been identified as the best prognosis of neonatal macrosomia, despite excellent HbA1C levels throughout pregnancy [9]. Moreover, glycemic fluctuations may adversely affects diabetic complications [10].

This case study first describes the clinical course of a type 1 diabetic pregnant patient suffering from hyperemesis gravidarum since the first trimester up until six months post-partum. Secondly, it documents the occurrence of sudden glycemic reductions and recurrent hypoglycemic events soon after beginning the lactation period.

**Case Presentation**

A 27-year-old, Venezuelan, type 1 diabetic patient, receiving treatment with multiple daily insulin injections (16 U glargine insulin plus 10 U prandial lispro insulin) came to the clinic for a regular check-up. She followed an adequate diet, was engaged in regular physical activity, and performed self-monitoring blood glucose tests three times a day. During the first visit to the clinic her HbA1C was at 6.2 %, there was no evidence of diabetic-related complications. She had rare symptomatic or unawareness hypoglycemic episodes. At age 24 she was diagnosed with hyperthyroidism. She was treated with 125 uglevothyroxine daily, and was tested for TSH receptor antibodies resulting in negative findings. Her thyroid-stimulating hormone (TSH) level was 3.96 uUI/ml. The patient’s blood pressure was 90/60 mmHg, her height was 159 cm, weight 50.7 kg and Body Mass Index (BMI) 20.6 kg/m² [2]. There were no outstanding findings in the physical examination. Minor adjustments in insulin and levothyroxine doses were done.

The second visit occurred three months later when the patient reported nausea, daily vomiting, and nocturnal and post-exercise hypoglycemia. The patient’s finger stick test glucose levels fluctuated from 40-290 mg/dL at any time of the day. She was found to be six weeks pregnant with hyperemesis gravidarum. Her HbA1C was at 6.7% and the TSH was at 4.4 uUI/ml. Her weight was 52 kg and blood pressure 90/70 mmHg. Glargine insulin was discontinued, prandial insulin was reduced to 6 U, and levemir 16 U was initiated. Domperidone 10 mg and folic acid 5 mg were prescribed.

One week later, the patient continued vomiting and experiencing severe and recurrent hypoglycemic events and rebound postprandial hyperglycemia. She was hospitalized, and a Continuous Insulin Infusion (CSII) (Paradigm Medtronic, Minneapolis, MN) and Glucose Monitoring System (CGMS, Medtronic, Northridge, CA) were placed [10,11] in order to improve glucose control [11-15]. During a short inpatient period, we conducted carbohydrate counting and insulin pump management sessions. The insulin infusion rate was determined based on the total MDI regimen previously used and adjusted according to daily glucose profiles.

The patient’s weight rose to 57.5 kg and 61 kg during the second and third trimester, respectively. She maintained normal blood pressures, did not have albuminuria, and sequential ultrasounds did not reveal fetal abnormalities. On week 39 the patient gave birth to a child of 2,700 g, 48 cm, and an Apgar score of 9/10, by cesarean section with no complications and no evidence of thyrotoxicosis. The patient received a 5% glucose IV infusion while the CSII was still in place. Immediately after delivery, the insulin infusion was stopped transitorily, and then re-started at a reduced infusion rate. Glucose levels ranged between 120-140 mg/dL during the following hours. The patient was counseled to adjust her food intake, and began breastfeeding eight hours after delivery. In the next three months, she noticed abrupt glycemic declines 10-15 minutes after she began breast feeding, followed by rebound hyperglycemia.

The patient was under observation to monitor the fluctuation glucose levels. She did not perform physical activity during this time. The patient ceased lactation and had gradual improvements in glucose control with few hypoglycemic levels compared to the previous months. After the patient stopped breastfeeding, she occasionally extracted breast milk manually to feed her baby and to avoid mastitis. Interestingly, doing so caused glycemic declines minutes after milk extraction. This observation was not documented with the CGMS.

The changes in HbA1C, blood glucose, the area under the curve above and below target levels, the standard deviation of glucose, and the glucose variation coefficient were analyzed during pregnancy, in the early post-partum period and three and six months later. Compared to the first trimester, the glucose variation coefficient declined from 55% to 13.5% and the area under the curve above target was reduced by 77% at the end of pregnancy, as illustrated in Table 1 and Figure 1. The average daily carbohydrate intake, average daily insulin,

<table>
<thead>
<tr>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third Trimester</th>
<th>Post Partum</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Initial</td>
<td>Late</td>
<td>Initial</td>
</tr>
<tr>
<td>Mean Blood Glucose (mg/dl)</td>
<td>139.0 ± 77.0</td>
<td>127.0 ± 49.0*</td>
<td>139.0 ± 44.0*</td>
</tr>
<tr>
<td>Average AUC above target (mg/dl)</td>
<td>30.6</td>
<td>18.6</td>
<td>10.5</td>
</tr>
<tr>
<td>Average AUV above target (mg/dl)</td>
<td>0</td>
<td>2.4</td>
<td>3.5</td>
</tr>
<tr>
<td>SD of Blood Glucose (mg/dl)</td>
<td>77.0</td>
<td>9.0</td>
<td>44.0</td>
</tr>
<tr>
<td>% CV of Blood glucose</td>
<td>55.4</td>
<td>38.6</td>
<td>38.9</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± SD

*P=0.001 as compare to initial first trimester

Table 1: Diabetes management during pregnancy, after delivery and it six months post partum in a type 1 diabetic patient with hyperemesis gravidarum
and the carbohydrate/insulin ratio during pregnancy and post-partum periods were obtained from the CGMS, as shown in Table 2. Total insulin requirements increased from 0.55 U/kg in the first trimester to 0.80 U/kg at the end of pregnancy; the changes in insulin demand were mainly driven from increments in insulin bolus, which changed from 0.23 to 0.45 U/kg in the same time period. Three days, one month and six months post-partum, insulin requirements dropped, as total daily insulin requirement was 0.44, 0.53 and 0.6 U/kg, respectively. Table 2 shows average daily insulin dose during different trimesters and in the post-partum period.

Due to hyperemesis, the absorption of levothyroxine was affected as TSH increased to 5.0 uU/ml on week 16 of pregnancy (Figure 2). Thus, levothyroxine was increased to 11.5 to 12.5 ug/dl and the TSH levels were maintained below 3.0 uUI/ml during the rest of the pregnancy.

Discussion

The present report describes a type 1 diabetic hypothyroid female patient with hyperemesis gravidarum who presented large glycemic fluctuations and hypoglycemia during the first weeks of pregnancy. Physical activity was not associated with the glucose fluctuations, as the patient was sedentary during the observation period. This patient did not report unnoted hypoglycemia prior to the pregnancy and, although she was diagnosed with diabetes twenty years ago, no other risk indicators for hypoglycemia were documented [16]. In addition to the glucose variability seen in type 1 diabetic patients [8,17], hyperemesis gravidarum predisposed severe hypoglycemic episodes. This condition precluded an optimal diabetes management and added high risks to the patient and fetus. The prenatal insulin treatment provided a good glycemic control as HbA1c was at 6.7%, but glucose levels fluctuated along the hyperglycemic and hypoglycemic range, predisposing obstetrical complications and congenital abnormalities, as aforementioned [2,3].

The intensive insulin treatment with CSII has not proven to be superior to MDI in pregnancy complicated by diabetes [13,18], and macrosomia has been documented in well-controlled type 1 diabetics with CSII [8,9]. In this patient, the glucose fluctuations were high and she suffered from frequent and severe hypoglycemic events, therefore, the use of both the CSII with the CGMS was clearly indicated [14,15].

As pregnancy progressed, glycemic control improved and glucose recordings significantly declined, similarly to previous studies [13,18]. The patient’s average carbohydrate intake increased throughout pregnancy and as expected, insulin needs increased. While basal insulin requirements remained relatively constant, the overall insulin demand was provided by the prandial insulin boluses, as reported previously [11-13].

In the post-partum period, the patient experienced unexpected glucose declines and hypoglycemic episodes 10-15 min after she initiated lactation as observed previously [19]. In non-diabetic women, no significant glucose changes occur during the period before or after lactation, nor do they develop hypoglycemia in response to lactation [20,21]. Fasting glucose demand was associated with an increased glucose production derived from glycogenolysis; while during breastfeeding, normal glucose levels were maintained by increasing insulin sensitivity [21]. Lactation has beneficial effects on glucose and lipid metabolism [22], and it was shown that the intensity of lactation improved fasting glucose and lower insulin levels as compared to non-lactating women [23].

In conclusion, in this type 1 diabetic, hypothyroid, pregnant patient complicated with hyperemesis, who gave birth to a normal child on week 39, the CGMS and CSII had a favorable effect to optimized glucose control. Thus, lactation-induced hypoglycemia could have played a role in the post-partum period, and hyperinsulinization does not seem to have occurred during the period before or after lactation, nor do they develop hypoglycemia in breastfeeding in type 1 diabetic patients [19]. In non-diabetic women, no significant glucose changes occur during the period before or after lactation, nor do they develop hypoglycemia in response to lactation [20,21]. Fasting glucose demand was associated with an increased glucose production derived from glycogenolysis; while during breastfeeding, normal glucose levels were maintained by increasing insulin sensitivity [21]. Lactation has beneficial effects on glucose and lipid metabolism [22], and it was shown that the intensity of lactation improved fasting glucose and lower insulin levels as compared to non-lactating women [23].

In conclusion, in this type 1 diabetic, hypothyroid, pregnant patient complicated with hyperemesis, who gave birth to a normal child on week 39, the CGMS and CSII had a favorable effect to optimized glucose control. Thus, lactation-induced hypoglycemia could have played a role in the post-delivery deterioration of glucose control in our patient.

Acknowledgments: Lic. Kathya Arrieta-Morera for assistance in literature search; to Lic. Grettel Rodríguez-Rodríguez for technical assistance and to Miss Constanza Gonzalez for their for technical assistance in preparing the manuscript.

---

Table 2: Daily carbohydrate intake, insulin doses, and carbohydrates/bolus insulin during pregnancy and post partum

<table>
<thead>
<tr>
<th></th>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third Trimester</th>
<th>Post Partum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>Late</td>
<td>Initial</td>
<td>Late</td>
</tr>
<tr>
<td>Average Daily Carbohydrates</td>
<td>163.6 ± 57.7</td>
<td>146.2 ± 32.9</td>
<td>203.2 ± 15.3</td>
<td>237.2 ± 32.9</td>
</tr>
<tr>
<td>Average Daily Insulin (U)</td>
<td>29.8 ± 1.7</td>
<td>36.5 ± 3.0</td>
<td>39.4 ± 3.3*</td>
<td>52.8 ± 3.4*</td>
</tr>
<tr>
<td>Total</td>
<td>17.5 ± 3.5</td>
<td>17.5 ± 0.1</td>
<td>17.6 ± 0.5</td>
<td>20.2 ± 0.5</td>
</tr>
<tr>
<td>Basal</td>
<td>12.2 ± 4.0</td>
<td>18.8 ± 3.1</td>
<td>22.2 ± 2.9</td>
<td>32.5 ± 3.4*</td>
</tr>
<tr>
<td>Bolus</td>
<td>13.3 ± 1.8</td>
<td>8.7 ± 0.98</td>
<td>9.3 ± 0.94</td>
<td>7.27 ± 0.2</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± SD

*P<0.005 as compare to initial first trimester
Figure 1: Glycemic fluctuations during early first trimester (A), late first trimester (B), early second trimester (C), late second trimester (D), and early third trimester (E) using the continuous monitoring system.
Financial Disclosure: Dr. JG. Jiménez-Montero has been on the insulin advisory board, received a research grant from Sanofi-Aventis and has been speaker for Merck Sharp & Dohme, and Novartis.

Consent: Patient has provided written consent for publication of this study.

References


Figure 2: Glycemic profile in the late third trimester, partum and early post partum periods (A), one month (B) and six months (C) post delivery using the continuous monitoring system.


